Oxford Biomedica PLC

Director's Dealing • May 3, 2022

National Storage Mechanism | Additional information

RNS Number : 1810K

Oxford Biomedica PLC

03 May 2022

Grant of options

London, UK - 03 May 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB) announces that on 29 April 2022 nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Oxford Biomedica 2015 Deferred Bonus Plan ("DBP") and the Oxford Biomedica 2015 Long Term Incentive Plan ("LTIP").

2022 LTIP and 2021 DBP Awards

Name of individual	Title	Number of shares subject to the 2021 DBP award	Number of shares subject to the 2022 LTIP award	Total shares over which options now held	Percentage of current issued share capital under option
John Dawson	Chief Executive Officer until 28 January 2022	52,118	-	827,669	0.9%
Stuart Paynter	Chief Financial Officer	35,171	96,100	347,623	0.4%
Dave Backer	Chief Commercial Officer	5,082 1	47,197	69,213	0.07%
Tim Kelly	Chief Executive Officer of OXB Solutions	-	38,528	191,305	0.2%
Lisa James	Chief People Officer	-	26,376	44,432	0.05%
James Miskin	Chief Technical Officer	16,168	38,135	181,357	0.2%
Kyriacos Mitrophanous	Chief Scientific Officer	16,321	38,501	198,510	0.2%
Nicholas Page	Chief Operations Officer	17,381	40,261	157,464	0.2%
Madduri Ravi Rao	Chief Medical Officer	-	28,318	60,136 2	0.06%
Jason Slingsby	Chief Business Officer	15,458	36,466	129,188	0.1%
Matthew Treagus	Chief Information Officer	5,314	38,501	56,412	0.06%
Natalie Walter	General Counsel	14,008	32,268	102,858	0.1%
Alex Lewis	Chief of Staff	-	9,423 3	78,650	0.08%

1 Dave Backer's DBP award were granted under the 2015 LTIP scheme as opposed to the 2015 Deferred Bonus Plan (DBP) due to US tax considerations and California regulatory considerations.

2 Dr. Madduri Rao's RSU joining options (see below) are included in this figure.

Under the terms of the DBP plan, the DBP awards will become exercisable as to one third of the shares subject to each award on each of the first three anniversaries of the grant date.

In line with best practice and current investor guidance the quantum of the 2022 LTIP to Stuart Paynter was scaled back from 175% of salary to 155% of salary. The quantum of 2022 LTIP granted to other members of SET was scaled back in line with Stuart Paynter's scale back percentage.

John Dawson did not received an award under the LTIP scheme for 2022.

The LTIP awards are subject to performance conditions. As set out in the 2021 Directors' Remuneration Report, the performance condition is based on TSR (40% of the award, assessed over the three years from grant); revenue growth (40% of the award, assessed over financial years 2022, 2023 and 2024) and strategic milestones (20% of the award). Details of the measures are included in the 2021 Directors' Remuneration Report, other than as regards the strategic milestones, which are commercially sensitive and will be disclosed in due course.

The LTIP awards granted Stuart Paynter will "vest" following the assessment of the performance condition, but will only be "released" so that they can be exercised following the end of a further two year holding period. The 2022 awards granted to other participants will vest and be released following the assessment of the performance condition.

RSU awards

3 In addition, on 29 April 2022 a nil-cost share option over 9,423 shares of 50 pence each in the Company was also granted under the LTIP scheme to Alexander Lewis, Chief of Staff.

As joining shares, a nil-cost share option over 31,818 shares of 50 pence each in the Company was also granted under the LTIP scheme to Dr Madduri Rao.

The RSU awards are not subject to performance conditions and will become exercisable from the third anniversary of the grant date.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

John Dawson

2.

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's  Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2022 LTIP Award

Price	Volume
Nil	Nil

2021 DBP Award

Price	Volume
Nil	52,118

d)

Aggregated information

-    Aggregate volume

-    Price

Awards granted over 52,118 shares in total

N/A

e)

Date of the transaction

2022-04-29

f)

Place of the transaction

Outside of trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Stuart Paynter

2.

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2022 LTIP Award

Price	Volume
Nil	96,100

2021 DBP Award

Price	Volume
Nil	35,171

d)

Aggregated information

-    Aggregate volume

-    Price

Awards granted over 131,271 shares in total

N/A

e)

Date of the transaction

2022-04-29

f)

Place of the transaction

Outside of trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Dave Backer

2.

Reason for the notification

a)

Position/status

Chief Commercial Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2022 LTIP Award

Price	Volume
Nil	47,197

2021 DBP Award

Price	Volume
Nil	5,082

d)

Aggregated information

-    Aggregate volume

-    Price

Awards granted over 52,279 shares in total

N/A

e)

Date of the transaction

2022-04-29

f)

Place of the transaction

Outside of trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Tim Kelly

2.

Reason for the notification

a)

Position/status

Chief Executive Officer of OXB Solutions

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2022 LTIP Award

Price	Volume
Nil	38,528

2021 DBP Award

Price	Volume
Nil	Nil

d)

Aggregated information

-    Aggregate volume

-    Price

Awards granted over 38,528 shares in total

N/A

e)

Date of the transaction

2022-04-29

f)

Place of the transaction

Outside of trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Lisa James

2.

Reason for the notification

a)

Position/status

Chief People Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2022 LTIP Award

Price	Volume
Nil	26,376

2021 DBP Award

Price	Volume
Nil	Nil

d)

Aggregated information

-    Aggregate volume

-    Price

Awards granted over 26,376 shares in total

N/A

e)

Date of the transaction

2022-04-29

f)

Place of the transaction

Outside of trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

James Miskin

2.

Reason for the notification

a)

Position/status

Chief Technical Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2022 LTIP Award

Price	Volume
Nil	38,135

2021 DBP Award

Price	Volume
Nil	16,168

d)

Aggregated information

-    Aggregate volume

-    Price

Awards granted over 54,303 shares in total

N/A

e)

Date of the transaction

2022-04-29

f)

Place of the transaction

Outside of trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Kyriacos Mitrophanous

2.

Reason for the notification

a)

Position/status

Chief Scientific Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2022LTIP Award

Price	Volume
Nil	38,501

2021 DBP Award

Price	Volume
Nil	16,321

d)

Aggregated information

-    Aggregate volume

-    Price

Awards granted over 54,822 shares in total

N/A

e)

Date of the transaction

2022-04-29

f)

Place of the transaction

Outside of trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Nicholas Page

2.

Reason for the notification

a)

Position/status

Chief Operations Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2022 LTIP Award

Price	Volume
Nil	40,261

2021 DBP Award

Price	Volume
Nil	17,381

d)

Aggregated information

-    Aggregate volume

-    Price

Awards granted over 57,642 shares in total

N/A

e)

Date of the transaction

2022-04-29

f)

Place of the transaction

Outside of trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Madduri Rao

2.

Reason for the notification

a)

Position/status

Chief Medical Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2022 LTIP Award

Price	Volume
Nil	28,318

2021 DBP Award

Price	Volume
Nil	Nil

2022 RSU Award

Price	Volume
Nil	31,818

d)

Aggregated information

-    Aggregate volume

-    Price

Awards granted over 60,136 shares in total

N/A

e)

Date of the transaction

2022-04-29

f)

Place of the transaction

Outside of trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Jason Slingsby

2.

Reason for the notification

a)

Position/status

Chief Business Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2022 LTIP Award

Price	Volume
Nil	36,466

2021 DBP Award

Price	Volume
Nil	15,458

d)

Aggregated information

-    Aggregate volume

-    Price

Awards granted over 51,924 shares in total

N/A

e)

Date of the transaction

2022-04-29

f)

Place of the transaction

Outside of trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Matthew Treagus

2.

Reason for the notification

a)

Position/status

Chief Information Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2022 LTIP Award

Price	Volume
Nil	38,501

2021 DBP Award

Price	Volume
Nil	5,314

d)

Aggregated information

-    Aggregate volume

-    Price

Awards granted over 43,815 shares in total

N/A

e)

Date of the transaction

2022-04-29

f)

Place of the transaction

Outside of trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Natalie Walter

2.

Reason for the notification

a)

Position/status

General Counsel

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2022 LTIP Award

Price	Volume
Nil	32,268

2021 DBP Award

Price	Volume
Nil	14,008

d)

Aggregated information

-    Aggregate volume

-    Price

Awards granted over 46,276 shares in total

N/A

e)

Date of the transaction

2022-04-29

f)

Place of the transaction

Outside of trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Alexander Lewis

2.

Reason for the notification

a)

Position/status

Chief of Staff

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of award over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2022 RSU Award

Price	Volume
Nil	9,243

d)

Aggregated information

-    Aggregate volume

-    Price

9,243

N/A

e)

Date of the transaction

2022-04-29

f)

Place of the transaction

Outside of trading venue

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: +44 (0)1865 783 000

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.  

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUPUCGAUPPGQW